TradingKey

關於 Natera Inc 公司

Natera, Inc. 是一家診斷公司，專注於分子檢測服務的開發和商業化，將其技術應用於女性健康、腫瘤學和器官健康領域。其無細胞脫氧核糖核酸 (cfDNA) 技術結合了其分子檢測，可從小到單細胞的樣本中可靠地測量整個基因組的許多信息區域。該公司的產品包括 Panorama 無創產前檢測 (NIPT)、Vistara、Horizon 攜帶者篩查、Spectrum 植入前遺傳學、Anora 流產檢測、Empower 和 Prospera。該公司還提供 Constellation，這是一個基於雲的軟件平臺，使實驗室客戶能夠通過雲訪問公司的算法和生物信息學，以驗證和啓動基於公司技術的測試。其 NIPT 可篩查胎兒和雙胞胎妊娠的染色體異常，通常需要從母親抽血。

公司簡介

公司代碼NTRA

公司名稱Natera Inc

上市日期Jul 02, 2015

成立日期2007

CEOMr. Steven Leonard (Steve) Chapman

員工數量4424

證券類型Ordinary Share

年結日Jul 02

公司地址13011 Mccallen Pass

城市AUSTIN

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編78753

電話16502499090

網址https://www.natera.com/

公司代碼NTRA

上市日期Jul 02, 2015

成立日期2007

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Matthew Rabinowitz, Ph.D.

Executive Chairman of the Board, Co-Founder

2.36M

-0.07%

Mr. Roelof Frederick Botha

Lead Independent Director

1.23M

+0.01%

Mr. Jonathan Sheena

Co-Founder, Director

317.91K

-1.07%

Mr. Daniel A Rabinowitz

Secretary, Chief Legal Officer

151.45K

-1.05%

Mr. John Fesko

President, Chief Business Officer

87.14K

-2.30%

Herman Rosenman, CPA

Independent Director

65.67K

+0.23%

Mr. Solomon Moshkevich

President - Clinical Diagnostics

51.71K

-9.61%

Dr. Monica Bertagnolli, M.D.

Independent Director

6.13K

+1.79%

Dr. Gail Boxer Marcus

Independent Director

5.29K

+2.74%

Mr. Steven Leonard (Steve) Chapman

Chief Executive Officer, Director

4.42K

-68.63%

名稱

名稱/職務

職務

持股

持股變動

Dr. Matthew Rabinowitz, Ph.D.

Executive Chairman of the Board, Co-Founder

2.36M

-0.07%

Mr. Roelof Frederick Botha

Lead Independent Director

1.23M

+0.01%

Mr. Jonathan Sheena

Co-Founder, Director

317.91K

-1.07%

Mr. Daniel A Rabinowitz

Secretary, Chief Legal Officer

151.45K

-1.05%

Mr. John Fesko

President, Chief Business Officer

87.14K

-2.30%

Herman Rosenman, CPA

Independent Director

65.67K

+0.23%

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Insurance carriers

472.65M

94.18%

Laboratory and other partners

20.83M

4.15%

Patients

8.35M

1.66%

地區USD

名稱

營收

佔比

United States

492.31M

98.10%

Europe, Middle East, India, Africa

6.05M

1.21%

Asia Pacific and Other

1.78M

0.36%

Americas, excluding U.S

1.69M

0.34%

業務

地區

業務USD

名稱

營收

佔比

Insurance carriers

472.65M

94.18%

Laboratory and other partners

20.83M

4.15%

Patients

8.35M

1.66%

股東統計

更新時間: 5月22日週四

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

9.04%

T. Rowe Price Associates, Inc.

7.64%

BlackRock Institutional Trust Company, N.A.

4.89%

JP Morgan Asset Management

4.68%

Farallon Capital Management, L.L.C.

3.33%

Other

70.42%

持股股東

佔比

The Vanguard Group, Inc.

9.04%

T. Rowe Price Associates, Inc.

7.64%

BlackRock Institutional Trust Company, N.A.

4.89%

JP Morgan Asset Management

4.68%

Farallon Capital Management, L.L.C.

3.33%

Other

70.42%

股東類型

持股股東

佔比

Investment Advisor

43.47%

Investment Advisor/Hedge Fund

28.31%

Hedge Fund

15.56%

Individual Investor

3.20%

Family Office

2.73%

Family Office

2.73%

Family Office

2.56%

Bank and Trust

1.57%

Research Firm

1.50%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

1128

132.70M

97.19%

+684.67K

2025Q1

1129

133.60M

97.90%

+2.21M

2024Q4

1001

128.40M

95.17%

-537.76K

2024Q3

896

125.06M

100.75%

-6.81M

2024Q2

850

125.13M

101.89%

-7.92M

2024Q1

798

124.30M

101.71%

-6.12M

2023Q4

781

119.55M

99.60%

-13.66M

2023Q3

787

122.52M

102.97%

-5.30M

2023Q2

792

116.72M

102.40%

-10.10M

2023Q1

788

115.81M

102.22%

-9.06M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

12.34M

9.04%

+53.13K

+0.43%

Mar 31, 2025

T. Rowe Price Associates, Inc.

10.43M

7.64%

+3.78M

+56.77%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.68M

4.89%

+212.90K

+3.29%

Mar 31, 2025

JP Morgan Asset Management

6.39M

4.68%

+531.80K

+9.07%

Mar 31, 2025

Farallon Capital Management, L.L.C.

4.55M

3.33%

+116.20K

+2.62%

Mar 31, 2025

Duquesne Family Office LLC

3.40M

2.49%

-164.52K

-4.61%

Mar 31, 2025

State Street Global Advisors (US)

3.37M

2.47%

+379.58K

+12.69%

Mar 31, 2025

Wellington Management Company, LLP

3.06M

2.24%

-180.35K

-5.57%

Mar 31, 2025

Fred Alger Management, LLC

2.60M

1.91%

-413.66K

-13.71%

Mar 31, 2025

RTW Investments L.P.

2.59M

1.9%

+223.00

+0.01%

Mar 31, 2025

持股ETF

更新時間: 7 小時前

機構名稱

佔比

Franklin Genomic Advancements ETF

6.73%

ARK Genomic Revolution ETF

5.45%

VanEck Biotech ETF

4.61%

Alger Weatherbie Enduring Growth ETF

4.54%

Global X Genomics & Biotechnology ETF

4.47%

First Trust Nasdaq Lux Digi Health Solutions ETF

4.22%

Alger 35 ETF

4.21%

Strategas Macro Momentum ETF

4.02%

Alger Mid Cap 40 ETF

3.63%

First Trust NYSE Arca Biotechnology Index Fund

3.59%

Franklin Genomic Advancements ETF

佔比6.73%

ARK Genomic Revolution ETF

佔比5.45%

VanEck Biotech ETF

佔比4.61%

Alger Weatherbie Enduring Growth ETF

佔比4.54%

Global X Genomics & Biotechnology ETF

佔比4.47%

First Trust Nasdaq Lux Digi Health Solutions ETF

佔比4.22%

Alger 35 ETF

佔比4.21%

Strategas Macro Momentum ETF

佔比4.02%

Alger Mid Cap 40 ETF

佔比3.63%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.59%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Natera Inc

134.580USD

Natera Inc

134.580

概覽

公司

財務